Loading organizations...
§ Venture Capital · TX, USA
Venture capital firm investing in early-stage and growth biotech and medical device companies, focused on underserved U.S. markets.
Founded in 2014 by Managing Director Aaron GL Fletcher and Partner Stella M Robertson, Bios Partners is a venture capital firm based in Fort Worth, Texas, investing in early stage seed opportunities and later stage growth companies within the biotech and medical device sectors. The organization focuses on advancing life sciences innovation by strategically allocating capital to underserved medical technology markets throughout the United States. Operating with a team of fourteen employees, the firm generates approximately five million dollars in annual revenue. The firm is currently targeting fifty million dollars for its second primary investment vehicle and has been actively marketing the Bios Clinical Opportunity Fund since July 2023. Key leadership managing these venture capital strategies includes the two founders alongside partners Leslie Kreis Jr and Amanda De La Garza, plus Vice President of Investments Blake Pate.
Key people at Bios Partners.
Bios Partners was founded in 2014 by Leslie W. Kreis, Jr. (Co-founder and Managing Partner).
Key people at Bios Partners.
Bios Partners has 7 tracked investments across 5 companies. The latest tracked deal is $19.0M Seed in Opus Genetics in September 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 22, 2021 | Opus Genetics | $19.0M Seed | Peter Ginsberg | Paul Manning |
| Dec 24, 2020 | ONL Therapeutics | $46.9M Series B | Bios Partners | — |
| Oct 15, 2020 | Azitra | $8.0M Other Equity | Juergen Eckhardt | Connecticut Innovations |
| Nov 13, 2019 | Actuate Therapeutics | $6.5M Series B | Bios Partners | DEFTA Partners, Kairos Ventures |
| May 17, 2019 | Actuate Therapeutics | $21.7M Series B | Kairos Ventures | DEFTA Partners, Tech Coast Angels |
| May 2, 2018 | Azitra | $2.1M Other Equity | Bios Partners, Daniel Wagner | KDT Ventures |
| Mar 23, 2017 | 410 Medical | $3.3M Series A | Bios Partners | Luke Roush |
Bios Partners was founded in 2014 by Leslie W. Kreis, Jr. (Co-founder and Managing Partner).
Bios Partners is a venture capital firm specializing in identifying and investing in advanced biotech innovations primarily in overlooked and under-invested regions of the United States, with a focus on the Central US. Their mission is to disrupt the geographic favoritism prevalent in venture capital, which tends to concentrate on coastal hubs like Silicon Valley and the Northeast, by supporting compelling scientific ventures outside these traditional centers. They invest in clinical-stage companies across diverse therapeutic areas, aiming to cultivate great science and bring innovative biotech solutions to market, thereby impacting the startup ecosystem by broadening geographic access to capital and expertise in biotech[1][2][5].
Founded in Fort Worth, Texas, Bios Partners was established by a team with a combined 80 years of experience spanning hedge funds, private equity, clinical drug development, and public pharma/biotech analysis. Key partners include Aaron G. L. Fletcher (Managing Partner and Co-Founder), Amanda De La Garza (Partner), Blake Pate (Vice President, Investments), and John Fucci (Partner). The firm evolved with a clear focus on addressing the imbalance in venture capital distribution by targeting early and growth-stage biotech companies in underserved U.S. markets, particularly the Central region, to unlock value in overlooked scientific innovation[3][5][6].
Bios Partners rides the trend of decentralizing biotech innovation funding, challenging the traditional concentration of venture capital in coastal regions. This timing is critical as scientific advancements are increasingly emerging nationwide, and the biotech sector demands broader geographic inclusion to fully realize its potential. Market forces such as rising biotech innovation outside traditional hubs and increasing investor interest in diverse pipelines favor Bios Partners’ approach. By enabling access to capital and expertise in underserved regions, Bios Partners influences the broader ecosystem by fostering regional biotech clusters and diversifying the innovation landscape[1][2][5].
Looking ahead, Bios Partners is poised to expand its influence by continuing to identify and nurture biotech ventures in underrepresented U.S. markets, potentially scaling its fund size and portfolio breadth. Trends shaping their journey include the growing recognition of regional biotech innovation, advances in gene and cell therapies, and increasing demand for novel therapeutics across multiple disease areas. Their role may evolve to become a key catalyst for regional biotech ecosystems, helping to democratize venture capital access and accelerate the commercialization of breakthrough biotech solutions nationwide[5][6]. This aligns with their founding mission to disrupt geographic favoritism and cultivate great science wherever it emerges.